Inclusion Criteria:

• Patients ≥18 years of age
• Histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective
• Karnofsky performance status of ≥70%
• Patients with an adequate hematological profile
• Patients with an adequate renal function
• Males and Females of childbearing potential must utilize a standard contraception method
• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Pregnant or breastfeeding patients
• Patients, who suffered from an acute cardiac event within the last 12 months
• Patients with active vascular disease, either myocardial or peripheral
• Patients with proliferative and/or vascular retinopathy
• Patients with known liver disease (alcoholic, drug/toxin induced, genetic, or autoimmune)
• Patients with known CNS metastatic disease
• Patients testing positive to one of the following viruses: HIV, HBV or HCV
• Patients receiving chemotherapy or radiotherapy within the last 4 weeks before enrolment
• Patients that have undergone major surgery within the last 4 weeks before enrolment
• Patients may not have received any other investigational agent within 4 weeks before enrolment.
• Patients with an ongoing requirement for an immunosuppressive treatment, including the use of glucocorticoids or cyclosporin, or with a history of chronic use of any such medication within the last 4 weeks before enrolment
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements